Roth Capital raised the firm’s price target on Verona Pharma (VRNA) to $92 from $83 and keeps a Buy rating on the shares after its Q1 results. The company’s Ohtuvayre’s launch performance continues to impress, achieving $71.3M in product sales in Q1 – up 95% from Q4 – and with prescriptions growing by 56%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $90 from $83 at BTIG
- Verona Pharma price target raised to $106 from $72 at Canaccord
- Verona Pharma’s Strong Market Performance and Strategic Advancements Justify Buy Rating and Increased Price Target
- Verona Pharma price target raised to $85 from $75 at H.C. Wainwright
- Verona Pharma Reports Strong Q1 2025 Earnings